Stuart Cobb is Chief Scientific Officer of Neoleukin Therapeutics, Inc.. Currently has a direct ownership of 27,591 shares of NLTX, which is worth approximately $0. The most recent transaction as insider was on Mar 26, 2025, when has been sold 7,200 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 27.6K
35.31% 3M change
35.31% 12M change
Total Value Held $0

Stuart Cobb Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 26 2025
BUY
Grant, award, or other acquisition
-
7,200 Added 20.7%
27,591 Common Stock
Mar 13 2024
BUY
Grant, award, or other acquisition
-
20,391 Added 50.0%
20,391 Common Stock
SC

Stuart Cobb

Chief Scientific Officer
New York, NY

Track Institutional and Insider Activities on NLTX

Follow Neoleukin Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NLTX shares.

Notify only if

Insider Trading

Get notified when an Neoleukin Therapeutics, Inc. insider buys or sells NLTX shares.

Notify only if

News

Receive news related to Neoleukin Therapeutics, Inc.

Track Activities on NLTX